PCI Pharma Services, a global CDMO specializing in innovative biopharma therapies, recently finalized the acquisition of Ajinomoto Althea, Inc., a US-based sterile fill-finish CDMO. This strategic move, part of a substantial $1 billion investment initiative, bolsters PCI’s capabilities in US drug product manufacturing, particularly in aseptic filling for prefilled syringes and cartridges. The acquisition marks a significant milestone in PCI’s expansion strategy across the United States and Europe, emphasizing the company’s commitment to scaling sterile manufacturing operations to address supply chain security and capacity constraints in the sterile injectable market.
The integration of Althea’s assets with PCI’s existing sterile fill-finish and advanced drug delivery operations establishes a cutting-edge manufacturing hub in San Diego, equipped with state-of-the-art facilities for large-scale aseptic production of prefilled syringes and cartridges. Althea’s expertise in oligonucleotides and peptides complements PCI’s proficiency in manufacturing complex formulations, including lyophilization for various injectables such as nanoparticles, mRNA, monoclonal antibodies, proteins, and other biologics. Moreover, the acquisition enhances PCI’s capabilities in high potent vial filling with lyophilization, positioning the company as a key player in filling high potent antibody-drug conjugates (ADCs) and reinforcing its foothold in the oncology therapeutics segment.
This strategic move aligns with PCI’s overarching strategy to advance drug delivery systems, particularly in prefilled syringes, cartridges, and autoinjectors. The company’s recent investments exceeding $365 million underscore its commitment to supporting the assembly and packaging of drug-device combination products, with a focus on injectable formats. By expanding infrastructure in the US and Europe, PCI aims to streamline the development, manufacturing, and commercialization of sterile drug products, catering to the rapidly evolving landscape of advanced drug delivery solutions.
In the US, PCI’s investments in Rockford, Illinois, will establish two state-of-the-art facilities dedicated to the assembly and packaging of prefilled syringes, autoinjectors, vials, and pen-cartridge combinations. These facilities will feature multiple high-speed production lines, ISO-standard testing capabilities, and advanced cartoning technology to support both clinical and commercial-scale operations. Similarly, in Europe, PCI’s recent acquisitions and expansions in Dundalk, Ireland, and Dublin highlight the company’s commitment to enhancing its commercial-scale packaging and device assembly capabilities for injectables and oral solid dose products.
Furthermore, PCI’s ongoing investments in its Leon, Spain facility demonstrate its dedication to innovation in drug manufacturing. The incorporation of a high-speed filling line for syringes and cartridges, equipped with isolator technology, underscores PCI’s commitment to providing flexible and reliable manufacturing solutions for biopharma customers. Additionally, the establishment of a cutting-edge biologics development lab further strengthens PCI’s upstream capabilities, positioning the company at the forefront of advanced drug delivery technologies.
By leveraging the expertise and resources gained through the acquisition of Ajinomoto Althea, PCI aims to streamline the development and commercialization of advanced drug delivery and drug-device combination products. This strategic integration underscores PCI’s unwavering dedication to enhancing patient outcomes through the delivery of life-changing therapies. Salim Haffar, CEO of PCI Pharma Services, emphasizes the company’s commitment to fostering turnkey customer partnerships and driving innovation in the field of biopharmaceutical manufacturing.
- The acquisition of Ajinomoto Althea strengthens PCI Pharma Services’ position in the US drug manufacturing landscape, particularly in sterile fill-finish operations.
- PCI’s strategic investments in advanced drug delivery systems and sterile manufacturing facilities underscore its commitment to innovation and customer-centric partnerships.
- The integration of Althea’s assets enhances PCI’s capabilities in manufacturing complex formulations, including oligonucleotides, peptides, nanoparticles, and high potent compounds.
- PCI’s expansion initiatives in the US and Europe aim to streamline the development, manufacturing, and commercialization of drug-device combination products, catering to the evolving needs of biopharma companies and patients.
Tags: lyophilization, biotech, drug delivery, upstream, oligonucleotides, biopharma, antibody-drug conjugates
Read more on pharmaceutical-technology.com